<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42570">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552147</url>
  </required_header>
  <id_info>
    <org_study_id>1502015384</org_study_id>
    <nct_id>NCT02552147</nct_id>
  </id_info>
  <brief_title>Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism</brief_title>
  <official_title>Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Autism Speaks</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some individuals with autism spectrum disorders (ASD) also demonstrate irritability or
      aggression, which can interfere with functioning. The purpose of this pilot study is to test
      whether transdermal nicotine is effective for irritability and/or aggression in adults with
      ASD using a double-blind, placebo-controlled clinical trial. Subjects will participate in
      three visits. At the first visit, subjects are screened for eligibility and enrolled.
      Baseline measures include rating scales and a frustrative computerized task. They will then
      wear seven days of transdermal nicotine or placebo. Visit two is on day seven and the study
      measures are repeated, vital signs and side effects monitored. Subjects will return for a
      third and final visit on day 21 to repeat the study measures performed during visit two.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Aberrant Behavior Checklist Irritability Subscale (ABC-I) score</measure>
    <time_frame>Baseline visit (day 0), visit 2 (day 7), visit 3 (day 21)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in frustration and irritability ratings during frustration-induction Go-NoGo task</measure>
    <time_frame>Baseline visit (day 0), visit 2 (day 7), visit 3 (day 21)</time_frame>
    <description>Subjects will perform a computerized frustration-induction task and complete a rating scale of irritability and frustration levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in State/Trait Anxiety Inventory (STAI) score</measure>
    <time_frame>Baseline visit (day 0), visit 2 (day 7), visit 3 (day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Social Responsiveness Scale-Adults (SRS-A)</measure>
    <time_frame>Baseline visit (day 0), visit 2 (day 7), visit 3 (day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in qualitative description of irritability and aggression symptoms</measure>
    <time_frame>visit 2 (day 7), visit 3 (day 21)</time_frame>
    <description>Brief qualitative reports of the patient's subjective experience will be recorded by asking &quot;In what ways did you find the patch helpful or harmful during the past week, if at all?&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Aggression</condition>
  <condition>Irritability</condition>
  <arm_group>
    <arm_group_label>Transdermal nicotine first, placebo last</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal placebo first, nicotine last</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal nicotine</intervention_name>
    <arm_group_label>Transdermal nicotine first, placebo last</arm_group_label>
    <arm_group_label>Transdermal placebo first, nicotine last</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transdermal placebo</intervention_name>
    <arm_group_label>Transdermal nicotine first, placebo last</arm_group_label>
    <arm_group_label>Transdermal placebo first, nicotine last</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-40

          -  Gender: All

          -  Language: Communicative in English

          -  Participants with a prior diagnosis of DSM-5 ASD at some point in their lifetime OR a
             DSM-4 diagnosis of Autism OR a DSM-4 diagnosis of Asperger's syndrome OR a DSM-4
             diagnosis of Pervasive Developmental Disorder Not Otherwise Specified.

          -  Aberrant Behavior Checklist - Irritability Subscale (ABC-I) score of 16 or higher

          -  No changes in psychotropic medications within the past 14 days.

          -  Either lives with a primary caregiver or closely engaged with a primary caregiver who
             interacts with the patient daily

          -  BMI &gt; 17.5 and &lt; 45

        Exclusion Criteria:

          -  Age &lt; 18 or &gt; 40

          -  History of significant intellectual impairment

          -  BMI &lt; 17.5 or &gt; 45

          -  Currently using tobacco or any nicotine products (transdermal, gum, e-cigarettes)

          -  Changes in psychotropic medication management within the past 14 days

          -  Previous allergy to transdermal patches

          -  Patients with heart rate &gt; 100 or &lt; 50 or known history of cardiac rhythm
             abnormalities

          -  Systolic blood pressure &gt; 150 or &lt; 95; diastolic blood pressure &gt; 90 or &lt; 50

          -  ABC-I score &lt; 16

          -  No primary caregiver, or primary caregiver unable to assist with rating scales
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan S Lewis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resident physician in psychiatry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alan S Lewis, MD, PhD</last_name>
    <phone>203-974-7300</phone>
    <phone_ext>7554</phone_ext>
    <email>alan.lewis@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerrit I Van Schalkwyk, MBChB</last_name>
    <phone>203-688-5900</phone>
    <email>gerrit.vanschalkwyk@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan S Lewis, MD, PhD</last_name>
      <phone>203-974-7300</phone>
      <phone_ext>7554</phone_ext>
      <email>alan.lewis@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Gerrit I Van Schalkwyk, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 3, 2016</lastchanged_date>
  <firstreceived_date>September 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Alan Lewis</investigator_full_name>
    <investigator_title>Resident physician in psychiatry</investigator_title>
  </responsible_party>
  <keyword>Autism spectrum disorder</keyword>
  <keyword>Aggression</keyword>
  <keyword>Irritability</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Nicotinic acetylcholine receptor</keyword>
  <keyword>Nicotinic agonist</keyword>
  <keyword>Adult autism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Cholinergic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
